VistaGen Therapeutics, Inc.
VTGN
$0.24
-$0.01-2.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.50M | 1.27M | 790.00K | 721.00K | 646.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.50M | 1.27M | 790.00K | 721.00K | 646.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.50M | 1.27M | 790.00K | 721.00K | 646.00K |
| SG&A Expenses | 18.06M | 18.51M | 18.67M | 17.09M | 16.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.17M | 73.39M | 70.69M | 66.19M | 60.29M |
| Operating Income | -69.66M | -72.12M | -69.90M | -65.47M | -59.65M |
| Income Before Tax | -67.61M | -69.68M | -67.05M | -62.24M | -55.77M |
| Income Tax Expenses | 7.00K | 7.00K | 0.00 | 0.00 | 7.00K |
| Earnings from Continuing Operations | -67.62 | -69.69 | -67.05 | -62.24 | -55.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.62M | -69.69M | -67.05M | -62.24M | -55.78M |
| EBIT | -69.66M | -72.12M | -69.90M | -65.47M | -59.65M |
| EBITDA | -69.45M | -71.92M | -69.71M | -65.30M | -59.49M |
| EPS Basic | -1.68 | -1.85 | -1.90 | -1.91 | -1.79 |
| Normalized Basic EPS | -1.05 | -1.15 | -1.18 | -1.19 | -1.12 |
| EPS Diluted | -1.68 | -1.85 | -1.90 | -1.91 | -1.79 |
| Normalized Diluted EPS | -1.05 | -1.15 | -1.18 | -1.19 | -1.12 |
| Average Basic Shares Outstanding | 163.29M | 152.24M | 141.47M | 129.95M | 124.83M |
| Average Diluted Shares Outstanding | 163.29M | 152.24M | 141.47M | 129.95M | 124.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |